Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | GAPDH | P04406 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26358941 | 1.00 | USP2 (0.51) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL8946366 | 0.90 | USP2 (0.53) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL6399736 | 0.87 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL17975737 | 0.87 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL4732553 | 0.87 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL2418301 | 0.87 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL11438817 | 0.85 | USP2 (0.53) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL20786060 | 0.82 | USP2 (0.57) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL9771282 | 0.82 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL14405371 | 0.81 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CA) | 2020-08-06 | — | — | US | disclosed |
| WO-2019046931-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-03-14 | — | — | WO | disclosed |
| US-20050009777-A1 | Non-natural carbon-linked nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1409503-A1 | NON-NATURAL CARBON-LINKED NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003011885-A1 | NON-NATURAL CARBON-LINKED NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
| EP-1000075-A4 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-1000075-A1 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| US-5907036-A | Procedures for obtaining ribo-C-nucleosides | ICN PHARMACEUTICALS, INC. (US) | 1999-05-25 | — | — | US | disclosed |
| WO-1999000399-A9 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999000399-A1 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| EP-0804447-A1 | PROCEDURES FOR OBTAINING RIBO-C-NUCLEOSIDES | ICN Pharmaceuticals, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996026212-A1 | PROCEDURES FOR OBTAINING RIBO-C-NUCLEOSIDES | ICN PHARMACEUTICALS, INC. (US) | 1996-08-29 | — | — | WO | disclosed |
| US-4451648-A | VIRICIDE BY MULTI-STEP PROCESS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1984-05-29 | — | — | US | disclosed |
| EP-0072977-A1 | Process for the production of 2-beta-D-ribofuranosylthiazole-4-carboxamide | Starks Associates, Incorporated (US) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | RAN, RANBP1, GDI2 | USP2 4401/4885POLB 1318/4885MEN1 1886/4885 |
| US-20050009777-A1 | Non-natural carbon-linked nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | USP2 4331/4885POLB 900/4885MEN1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.